[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457979":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":133,"collaborators":135,"id":149,"slug":150,"hasResults":151,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":151,"sex":157,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":32,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":171,"overallStatus":50,"whyStopped":32,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},{"fullName":5,"class":6},"Oxford University Clinical Research Unit Indonesia","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin 1000mg extended release (XR) once daily + standard-of-care MDT","EXPERIMENTAL","Metformin hydrochloride 500mg XR tablets once daily by mouth for 2 weeks, escalating to a target dose of 1000mg XR once daily for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.",[13],"Drug: Metformin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo + MDT","PLACEBO_COMPARATOR","Matching metformin placebo tablets once daily by mouth for 2 weeks, escalating to two tablets for another 22 weeks. Each participant will receive the same number of tablets made up of metformin and placebo to maintain the blinding.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Metformin","Metformin 1000mg XR OD + standard-of-care MDT",[9],[27],"Glumin XR",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","Placebo + standard-of-care MDT",[15],null,[34],{"name":35,"affiliation":36,"role":37},"Hardiyanto Soebono, Prof.Dr.dr","Center of Tropical Medicine, University of Gadjah Mada","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":32,"email":43},"Marlous Grijsen, MD, PhD","CONTACT","62-21-23599099","mgrijsen@oucru.org",{"name":45,"role":41,"phone":42,"phoneExt":32,"email":46},"Mutia Rahardjani, MD, MSc","mrahardjani@oucru.org",[48,73,91,101,118,124],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Sitanala Leprosy Hospital","RECRUITING","Tangerang","Banten","15121","Indonesia","ID",{"type":57,"coordinates":58},"Point",[59,60],106.63,-6.17806,{"lat":60,"lon":59},[63,67,71],{"name":64,"role":41,"phone":65,"phoneExt":32,"email":66},"Nandya A Mulyadi, MD","+622123599099","nmulyadi@oucru.org",{"name":68,"role":41,"phone":69,"phoneExt":32,"email":70},"Prima K Esti, MD, MEpid","+628128187632","prima_kartika@yahoo.com",{"name":72,"role":37,"phone":32,"phoneExt":32,"email":32},"Prima K Esti, MD",{"facility":74,"status":50,"city":75,"state":76,"zip":77,"country":54,"countryCode":55,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"Palangga Health Center","Makassar","South Sulawesi","92161",{"type":57,"coordinates":79},[80,81],119.43194,-5.14861,{"lat":81,"lon":80},[84,85,89],{"name":64,"role":41,"phone":65,"phoneExt":32,"email":66},{"name":86,"role":41,"phone":87,"phoneExt":32,"email":88},"Sri Vitayani, MD, PhD","+6281341821336","srivita711@gmail.com",{"name":90,"role":37,"phone":32,"phoneExt":32,"email":32},"Sri Vitayani, MD,PhD",{"facility":92,"status":50,"city":75,"state":76,"zip":93,"country":54,"countryCode":55,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},"Bajeng Health Center","92211",{"type":57,"coordinates":95},[80,81],{"lat":81,"lon":80},[98,99,100],{"name":64,"role":41,"phone":65,"phoneExt":32,"email":66},{"name":86,"role":41,"phone":87,"phoneExt":32,"email":88},{"name":86,"role":37,"phone":32,"phoneExt":32,"email":32},{"facility":102,"status":50,"city":103,"state":104,"zip":32,"country":54,"countryCode":55,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Abe Pantai Community Health Center","Jayapura","Special Region of Papua",{"type":57,"coordinates":106},[107,108],140.71813,-2.53371,{"lat":108,"lon":107},[111,113,117],{"name":112,"role":41,"phone":65,"phoneExt":32,"email":66},"Nadya A Mulyadi, MD",{"name":114,"role":41,"phone":115,"phoneExt":32,"email":116},"Hana Krismawati, MSc","+6282399399799","hkrismawati@gmail.com",{"name":114,"role":37,"phone":32,"phoneExt":32,"email":32},{"facility":119,"status":120,"city":103,"state":104,"zip":32,"country":54,"countryCode":55,"cosmosGeoPoint":121,"geoPoint":123,"contacts":32},"Hamadi Community Health Center","WITHDRAWN",{"type":57,"coordinates":122},[107,108],{"lat":108,"lon":107},{"facility":125,"status":50,"city":103,"state":104,"zip":32,"country":54,"countryCode":55,"cosmosGeoPoint":126,"geoPoint":128,"contacts":129},"Jayapura Utara Community Health Center",{"type":57,"coordinates":127},[107,108],{"lat":108,"lon":107},[130,131,132],{"name":64,"role":41,"phone":65,"phoneExt":32,"email":66},{"name":114,"role":41,"phone":115,"phoneExt":32,"email":116},{"name":114,"role":37,"phone":32,"phoneExt":32,"email":32},{"type":134,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[136,139,141,143,145,147],{"name":137,"class":138},"University of Gadjah Mada, Faculty of Medicine","UNKNOWN",{"name":140,"class":138},"University of Diponegoro",{"name":142,"class":138},"Papua Agency of Health Research and Development (NIHRD)",{"name":144,"class":6},"London School of Hygiene and Tropical Medicine",{"name":146,"class":6},"Radboud University Medical Center",{"name":148,"class":138},"Oxford University Clinical Research Unit","100457979","phase-2-efficacy-and-tolerability-of-adjunct-metformin-for-multibacillary-leprosy-100457979",false,"NCT05243654","Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy","Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in Indonesia","MetLep","Inclusion Criteria:\n\n* Participant is a male or female, aged ≥18 and ≤65 years.\n* Participant is newly diagnosed with MB leprosy and has been receiving MDT ≤ 28 days.\n* Participant is willing and able to give informed consent for participation in the trial.\n* Participant is willing to adhere to study follow-up schedule for 48 weeks.\n\nExclusion Criteria:\n\n* Participant has received MDT \\>28 days for the current episode of MB leprosy, prior to study enrolment.\n* Presence of leprosy reaction and\u002For nerve function impairment requiring systemic corticosteroids on screening\u002Fenrolment evaluation.\n* Participants who have been treated for leprosy in the past.\n* Chronic systemic corticosteroid use for any other medical condition on screening evaluation (chronic use defined as ≥ 2 weeks).\n* History of diabetes mellitus or diabetes mellitus diagnosed on screening evaluation (random blood glucose is elevated ≥200 mg\u002FdL (or ≥11,1 mmol\u002FL) or fasting blood glucose ≥ 126 mg\u002FdL (or ≥7.0 mmol\u002FL)).\n* History of hypoglycaemia (random blood glucose \\\u003C55 mg\u002FdL (or \\\u003C3.0 mmol\u002FL).\n* History of cardiac failure, ischaemic heart disease, alcoholism, history of lactic acidosis or states associated with lactic acidosis such as shock or pulmonary insufficiency, and conditions associated with hypoxia.\n* History of intolerance or hypersensitivity to metformin.\n* Estimated glomerular filtration rate (eGFR) ≤30 mL\u002Fmin\u002F1.73m2 calculated by the CKDEPI equation.\n* AST or ALT ≥3 times the upper limit of normal (ULN) on screening evaluation.\n* Any serious medical condition for which participation in the trial, as judged by the investigator or treating physician, could compromise the well-being of the subject or prevent, limit or confound protocol-specified assessments.\n* HIV-positive on screening evaluation.\n* Female participant of childbearing age who is pregnant (clinically confirmed or urine dipstick for human chorionic gonadotrophin hormone) or breastfeeding.\n* Use of metformin within 12 weeks prior to study enrolment.\n* Use of other regular hypoglycaemic agents, including insulin.\n* Participation in another research trial involving an investigational product within 12 weeks prior to study enrolment.","ALL","18 Years","65 Years",{"count":161,"type":162},166,"ESTIMATED","INTERVENTIONAL",[165],"PHASE2","This trial aims to evaluate the efficacy, tolerability and safety of adjunct metformin added to standard-of-care multi-drug therapy (MDT) in patients with multibacillary leprosy, and explore its effects on immunological endpoints. A double-blind, placebo controlled proof-of-concept trial will be performed in which patients with newly diagnosed multibacillary leprosy will be randomized (1:1) to metformin 1000mg OD versus placebo for 24 weeks in addition to MDT during 48 weeks.\n\nThe main research question is whether adjunctive metformin, combined with MDT, will improve the clinical outcomes of patients with multibacillary leprosy by mitigating leprosy reactions, thereby reducing nerve damage and corticosteroid use and its associated morbidity. The second aim is to explore whether adjunct metformin, added to MDT, has an acceptable tolerability and safety in patients with multibacillary leprosy.",[168,169,170],"Leprosy","Leprosy, Multibacillary","Neglected Tropical Diseases",[168,172,173],"Multibacillary leprosy","Skin-NTD","2025-08-04",{"date":176,"type":177},"2025-08-07","ACTUAL",{"date":179,"type":177},"2022-10-01",{"date":181,"type":162},"2026-09-30",{"name":5,"class":6},6]